EA201491532A1 - Фармацевтические композиции для использования в комплексной терапии - Google Patents

Фармацевтические композиции для использования в комплексной терапии

Info

Publication number
EA201491532A1
EA201491532A1 EA201491532A EA201491532A EA201491532A1 EA 201491532 A1 EA201491532 A1 EA 201491532A1 EA 201491532 A EA201491532 A EA 201491532A EA 201491532 A EA201491532 A EA 201491532A EA 201491532 A1 EA201491532 A1 EA 201491532A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
tesofensin
complex therapy
metoprolol
unaffected
Prior art date
Application number
EA201491532A
Other languages
English (en)
Other versions
EA029543B1 (ru
Inventor
Хенрик Бьерк Хансен
Мортен Груннет
Бо Йорт Бентсен
Ларс Хювелед-Нильсен
Йерген Буус Лассен
Клаус Суннгреен
Original Assignee
Неуросерч А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Неуросерч А/С filed Critical Неуросерч А/С
Publication of EA201491532A1 publication Critical patent/EA201491532A1/ru
Publication of EA029543B1 publication Critical patent/EA029543B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к применению фармацевтической композиции, содержащей терапевтически эффективную комбинацию тезофенсина и метопролола, для предотвращения сердечно-сосудистых побочных эффектов тезофенсина, оставляя при этом незатронутой устойчивую ингибиторную эффективность тезофенсина на потребление пищи и потерю веса тела.
EA201491532A 2012-02-16 2013-02-14 Способ лечения, профилактики или уменьшения сердечно-сосудистых побочных эффектов тезофенсина EA029543B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261599623P 2012-02-16 2012-02-16
DKPA201270076 2012-02-16
PCT/EP2013/052941 WO2013120935A1 (en) 2012-02-16 2013-02-14 Pharmaceutical compositions for combination therapy

Publications (2)

Publication Number Publication Date
EA201491532A1 true EA201491532A1 (ru) 2015-01-30
EA029543B1 EA029543B1 (ru) 2018-04-30

Family

ID=48983571

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491532A EA029543B1 (ru) 2012-02-16 2013-02-14 Способ лечения, профилактики или уменьшения сердечно-сосудистых побочных эффектов тезофенсина

Country Status (15)

Country Link
US (5) US9211271B2 (ru)
EP (1) EP2814473B1 (ru)
JP (1) JP6203760B2 (ru)
CN (3) CN104244935A (ru)
AU (1) AU2013220424B2 (ru)
CA (1) CA2864264C (ru)
DK (1) DK2814473T3 (ru)
EA (1) EA029543B1 (ru)
ES (1) ES2704987T3 (ru)
HK (1) HK1204946A1 (ru)
HR (1) HRP20190050T1 (ru)
LT (1) LT2814473T (ru)
PL (1) PL2814473T3 (ru)
SI (1) SI2814473T1 (ru)
WO (1) WO2013120935A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211271B2 (en) * 2012-02-16 2015-12-15 Saniona A/S Pharmaceutical compositions for combination therapy
US20160192039A1 (en) * 2013-12-28 2016-06-30 Intel Corporation System and method for device action and configuration based on user context detection from sensors in peripheral devices
SG11201706899VA (en) * 2015-03-03 2017-09-28 Saniona As Tesofensine, beta blocker combination formulation
EP3402473A1 (en) 2016-01-15 2018-11-21 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
WO2018046599A1 (en) 2016-09-07 2018-03-15 Saniona A/S Tesofensine compositions
WO2020144146A1 (en) 2019-01-07 2020-07-16 Saniona A/S Tesofensine for reduction of body weight in prader-willi patients
CN110297826B (zh) * 2019-05-31 2020-12-11 南京理工大学 基于json动态解析卫星遥测数据的方法
EP4138830A1 (en) 2020-04-22 2023-03-01 Saniona A/S Treatment of hypothalamic obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576617B1 (en) * 1991-03-18 1996-08-07 Sepracor, Inc. Composition and method containing optically pure (s) metoprolol
HU228356B1 (en) 1996-02-22 2013-03-28 Neurosearch As Tropane-derivatives, inhibiting neurotransmitter re-uptake, their preparation, pharmaceutical compositions containing them and use of the compounds
JP2007519646A (ja) 2004-01-22 2007-07-19 ノイロサーチ アクティーゼルスカブ 体重の持続的低減のための化合物
US20110118304A1 (en) 2007-11-20 2011-05-19 Neurosearch A/S Method for treating over-eating disorders
WO2009080693A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
CA2709861A1 (en) 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical compositions
WO2011100659A2 (en) 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
US9211271B2 (en) * 2012-02-16 2015-12-15 Saniona A/S Pharmaceutical compositions for combination therapy
SG11201706899VA (en) * 2015-03-03 2017-09-28 Saniona As Tesofensine, beta blocker combination formulation

Also Published As

Publication number Publication date
CN108434129A (zh) 2018-08-24
HRP20190050T1 (hr) 2019-03-08
AU2013220424B2 (en) 2017-03-23
EP2814473A1 (en) 2014-12-24
US20150025107A1 (en) 2015-01-22
EA029543B1 (ru) 2018-04-30
AU2013220424A1 (en) 2014-09-25
WO2013120935A1 (en) 2013-08-22
US20160074344A1 (en) 2016-03-17
CN104244935A (zh) 2014-12-24
US9387184B2 (en) 2016-07-12
CA2864264C (en) 2020-05-05
JP2015508765A (ja) 2015-03-23
CN108853071A (zh) 2018-11-23
CA2864264A1 (en) 2013-08-22
SI2814473T1 (sl) 2019-03-29
DK2814473T3 (en) 2019-01-28
HK1204946A1 (en) 2015-12-11
US20180185304A1 (en) 2018-07-05
EP2814473B1 (en) 2018-10-10
JP6203760B2 (ja) 2017-09-27
US20220016055A1 (en) 2022-01-20
US9211271B2 (en) 2015-12-15
LT2814473T (lt) 2019-01-25
ES2704987T3 (es) 2019-03-21
PL2814473T3 (pl) 2019-06-28
US20170007557A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
EA201491532A1 (ru) Фармацевтические композиции для использования в комплексной терапии
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
IN2014DN09434A (ru)
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201500314A1 (ru) Лекарственные формы энзалутамида
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX2021000715A (es) Composiciones y metodos para tratar trastornos metabolicos.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
WO2013185764A3 (en) Pharmaceutical compositions for combination therapy
WO2012135528A3 (en) Galectin-3c combination therapy for human cancer
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201301083A1 (ru) Комплексные соединения железа(iii) для лечения и профилактики симптомов железодефицита и железодефицитной анемии
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM